A proposed bailout for A-T patients?
Gatti
Richard A
RA
Perlman
Susan
S
D000163:Acquired Immunodeficiency Syndrome / Q000139:chemically induced; D000367:Age Factors; D001260:Ataxia Telangiectasia / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D064007:Ataxia Telangiectasia Mutated Proteins; D001623:Betamethasone / Q000009:adverse effects / Q000627:therapeutic use*; D018797:Cell Cycle Proteins / Q000235:genetics; D002531:Cerebellum / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004268:DNA-Binding Proteins / Q000235:genetics; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D018570:Risk Assessment; D013995:Time; D013997:Time Factors; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000235:genetics
D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D005938:Glucocorticoids; D025521:Tumor Suppressor Proteins; D001623:Betamethasone; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases